SRC‐1 inhibitors can be combined with immunotherapy to overcome resistance to PD‐1/PD‐L1 inhibitors.[30] In colorectal cancer models, combination therapy with an SRC‐1 inhibitor and PD‐L1 antibody resulted in tumor regression rates increasing more than two‐fold compared to monotherapy, accompanied by a three‐fold increase in CD8+ T‐cell infiltration.[30] Notably, our findings suggest that the inhibition of SRC‐1 may serve as a therapeutic target for mitigating PNI in pancreatic cancer. Here, CD8A is linked to familial pancreatic carcinoma.